<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251602</url>
  </required_header>
  <id_info>
    <org_study_id>AG0059</org_study_id>
    <nct_id>NCT00251602</nct_id>
  </id_info>
  <brief_title>Analysis of Atropine and Propranolol Induced Changes</brief_title>
  <official_title>Wavelet Transform and Pharmacodynamic Analysis of Atropine and Propranolol Induced Changes in Human Heart Rate Variability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn the effects of genetic make up on response to the drugs
      atropine and propranolol, to examine how changes in heart rate and blood pressure can be
      measured, and to test a new statistical analysis method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers will be recruited and screened for eligibility. Participants will be
      placed into three possible groups based on genetic information obtained during screening.
      Rolling admissions will continue until at least 10 participants have been recruited for each
      genetic group. Participants will be randomly assigned to receive either the control
      (propranolol and saline) or combined drug (propranolol and atropine) treatment in a
      non-blinded fashion. The participant will return over one week later to receive the alternate
      treatment. Continuous heart rate/blood pressure data will be recorded until the end of the
      study period. Respiratory rate will be maintained at a fixed rate. Participants will undergo
      an orthostasis task, receive the drug or control infusions, and blood samples will then be
      obtained to determine drug concentrations at specific time intervals. Several relatively new
      mathematical techniques will be applied to the data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in heart rate and blood pressure</measure>
    <time_frame>every 2 minutes during drug infusions and every 10 minutes during the remainder of the study time</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>II ACE genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ID ACE genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD ACE genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>II ACE genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ID ACE genotype</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DD ACE genotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>One-time 0.25 ml/min infusion over 30 minutes</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers

          -  Ages 21-40

          -  Body Mass Index &gt;18.0 and &lt;27.0

        Exclusion Criteria:

          -  History of any chronic illnesses including cardiac diseases and bleeding problems

          -  Drug use of any kind

          -  Participation in any clinical trial within the last month

          -  Tobacco use and/or alcohol abuse

          -  Use of dietary supplements and unwillingness to refrain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shari M. Ling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging, Clinical Research Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute on Aging, Harbor Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 1981 Jul 10;213(4504):220-2.</citation>
    <PMID>6166045</PMID>
  </reference>
  <reference>
    <citation>Craft N, Schwartz JB. Effects of age on intrinsic heart rate, heart rate variability, and AV conduction in healthy humans. Am J Physiol. 1995 Apr;268(4 Pt 2):H1441-52.</citation>
    <PMID>7733345</PMID>
  </reference>
  <reference>
    <citation>Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga E, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res. 1986 Aug;59(2):178-93.</citation>
    <PMID>2874900</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2005</study_first_submitted>
  <study_first_submitted_qc>November 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2005</study_first_posted>
  <last_update_submitted>August 3, 2012</last_update_submitted>
  <last_update_submitted_qc>August 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart rate variability</keyword>
  <keyword>gene response</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

